Optically active substituted phenylalkylamine derivatives represented by general formula (1) or pharmaceutically acceptable salts thereof and medicinal uses of the same: wherein A represents optionally substituted phenyl or thienyl; X1 represents hydrogen, halogeno, hydroxy or optionally substituted C¿1-5? alkoxy; R?1 and R2¿ are the same or different and each represents hydrogen, C¿1-7? alkyl, C3-7 alkenyl or C3-7 alkynyl; R?3¿ represents C¿1-10? alkyl, C2-10 alkenyl or C2-10 alkynyl; n is an integer of from 2 to 5; and m is an integer of from 1 to 4. These compounds have an excellent sigma 1 receptor antagonism and are efficacious in the treatment of schizophrenia, depression, anxiety and cerebrovascular disorders/senile problem behaviors, and cognition and motor function disorders caused by nerve degeneration diseases such as Alzheimer's, Parkinson's and Huntington's diseases. They are also efficacious in the treatment of addiction caused by drug abuse.